Friday, May 9, 2025
5/9/2025
Biochemical Strategy to Avert Microbial Drug Resistance - PROJECT SUMMARY/ABSTRACT The goal of the proposed research is to develop a generalizable antimicrobial strategy that averts the onset of resistance. The proposed antiviral agent has a mechanism of action that relies on the function of a pathogenic protein rather than its inhibition. Specifically, the agent is a cytotoxic variant of a human enzyme, ribonuclease 1 (RNase 1), that is cloaked and thus inactive as a catalyst. The cloak is removable only by a pathogenic protease that is essential for the lifecycle of the pathogen. SARS-CoV-2 will serve as a model pathogen in the study. The goal will be attained by (1) identifying an optimal amino acid sequence that is cleaved by the 3CLpro protease of SARS-CoV-2 but not by endogenous human proteases, (2) using that sequence and intein-mediated cis- splicing to create a cyclic RNase 1 zymogen, and (3) demonstrating the ability of the zymogen to kill human lung cells that express 3CLpro and that are infected by SARS-CoV-2. Because the activated zymogen can also destroy the genome of an RNA virus like SARS-CoV-2, it could eradicate the viral reservoir in patients. A notable feature of the strategy is its modularity: the protease-cleavage sequence is a cassette that can be altered to match the specificity of pathogenic proteases for the treatment of other infectious diseases.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).